Pharmacokinetics of L-carnitine
AM Evans, G Fornasini - Clinical pharmacokinetics, 2003 - Springer
L-Carnitine is a naturally occurring compound that facilitates the transport of fatty acids into
mitochondria for β-oxidation. Exogenous L-carnitine is used clinically for the treatment of …
mitochondria for β-oxidation. Exogenous L-carnitine is used clinically for the treatment of …
Trimethylamine: metabolic, pharmacokinetic and safety aspects
MA Bain, G Fornasini, AM Evans - Current drug metabolism, 2005 - ingentaconnect.com
… that the oral bioavailability of Lcarnitine is higher when administered as whole food than
compared to the administration of the pure chemical form (reviewed by Evans and Fornasini [66]…
compared to the administration of the pure chemical form (reviewed by Evans and Fornasini [66]…
Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis
MA Bain, R Faull, G Fornasini, RW Milne… - Nephrology Dialysis …, 2006 - academic.oup.com
… , Austria) and immediately placed on ice prior to centrifugation (3000 g ) at 4C for 10 min. …
Bain MA, Faull R, Fornasini G et al . Quantifying trimethylamine and trimethylamine- N -oxide in …
Bain MA, Faull R, Fornasini G et al . Quantifying trimethylamine and trimethylamine- N -oxide in …
The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system (“TIME CLOCK®” system)
…, G Hooper, N Monti, MS Benedetti, G Fornasini… - Journal of controlled …, 1997 - Elsevier
In the early stages of product development for novel colonic delivery systems, considerable
time can be lost in establishing the likely potential of any given research strategy because of …
time can be lost in establishing the likely potential of any given research strategy because of …
Pharmacokinetics of L‐carnitine in patients with end‐stage renal disease undergoing long‐term hemodialysis
AM Evans, R Faull, G Fornasini… - Clinical …, 2000 - Wiley Online Library
Objective L‐Carnitine is an endogenous molecule involved in fatty acid metabolism. Secondary
carnitine deficiency may develop in patients with end‐stage renal disease undergoing …
carnitine deficiency may develop in patients with end‐stage renal disease undergoing …
[HTML][HTML] Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease
… various reporting methods (per g wet weight, per g dry weight, per g of noncollagen protein),
… to the present study (1 to 4 μmol/g tissue). Bellinghieri et al 22 also reported that the levels …
… to the present study (1 to 4 μmol/g tissue). Bellinghieri et al 22 also reported that the levels …
Determination of the reference range of endogenous plasma carnitines in healthy adults
…, AM Evans, DH Chace, G Fornasini - Annals of clinical …, 2008 - journals.sagepub.com
Background l-carnitine is an endogenous substance, vital in the transport of fatty acids across
the inner mitochondrial membrane for oxidation. Disturbances in carnitine homeostasis …
the inner mitochondrial membrane for oxidation. Disturbances in carnitine homeostasis …
Recombinant adenosine deaminase ameliorates inflammation, vascular disease, and fibrosis in preclinical models of systemic sclerosis
…, F Groeber, C Reuter, GF Fornasini… - Arthritis & …, 2020 - Wiley Online Library
Objective Systemic sclerosis ( SS c) is characterized by fibrosis, vascular disease, and
inflammation. Adenosine signaling plays a central role in fibroblast activation. We undertook this …
inflammation. Adenosine signaling plays a central role in fibroblast activation. We undertook this …
Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated perfused in situ rat liver.
CH Chou, AM Evans, G Fornasini, M Rowland - Drug metabolism and …, 1993 - ASPET
… With increasing length of the alkyl chain, there was a significant increase in the volume of
distribution in the liver (0.85 +/- 0.12 ml/g for methyl and 4.87 +/- 1.27 ml/g for pentyl), which led …
distribution in the liver (0.85 +/- 0.12 ml/g for methyl and 4.87 +/- 1.27 ml/g for pentyl), which led …
A pharmacokinetic model for L‐carnitine in patients receiving haemodialysis
G Fornasini, RN Upton… - British journal of clinical …, 2007 - Wiley Online Library
A pharmacokinetic model for L‐carnitine in patients receiving haemodialysis - Fornasini - …
solution for injection of L-carnitine (Carnitor ® 1 g in 5 ml; Sigma-tau Pharmaceuticals, Inc., …
solution for injection of L-carnitine (Carnitor ® 1 g in 5 ml; Sigma-tau Pharmaceuticals, Inc., …